Adverse Drug Reaction Reporting Systems
"Adverse Drug Reaction Reporting Systems" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions.
| Descriptor ID |
D016907
|
| MeSH Number(s) |
E05.337.800.120 N02.421.668.320.120
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Adverse Drug Reaction Reporting Systems".
Below are MeSH descriptors whose meaning is more specific than "Adverse Drug Reaction Reporting Systems".
This graph shows the total number of publications written about "Adverse Drug Reaction Reporting Systems" by people in this website by year, and whether "Adverse Drug Reaction Reporting Systems" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 3 | 4 |
| 2008 | 3 | 0 | 3 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adverse Drug Reaction Reporting Systems" by people in Profiles.
-
Yukselen Z, Raju AKV, Kumar PA, Ujjawal A, Dasari M, Parajuli S, Nakhla M, Bansal K, Ganatra S, Dani SS. A Real-World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten. Am J Cardiovasc Drugs. 2024 Nov; 24(6):791-799.
-
Bhanushali KB, Asnani HK, Nair A, Ganatra S, Dani SS. Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials. Curr Probl Cardiol. 2024 Sep; 49(9):102664.
-
Batra A, Patel B, Addison D, Baldassarre LA, Desai N, Weintraub N, Deswal A, Hussain Z, Brown SA, Ganatra S, Agarwala V, Parikh PM, Fradley M, Ghosh A, Guha A. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart. 2021 12; 8(2).
-
Rawat BPS, Jagannatha A, Liu F, Yu H. Inferring ADR causality by predicting the Naranjo Score from Clinical Notes. AMIA Annu Symp Proc. 2020; 2020:1041-1049.
-
Honvo G, Bannuru RR, Bruy?re O, Rannou F, Herrero-Beaumont G, Uebelhart D, Cooper C, Arden N, Conaghan PG, Reginster JY, Thomas T, McAlindon T. Recommendations for the Reporting of Harms in Manuscripts on Clinical Trials Assessing Osteoarthritis Drugs: A Consensus Statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Drugs Aging. 2019 04; 36(Suppl 1):145-159.
-
Liu F, Jagannatha A, Yu H. Towards Drug Safety Surveillance and Pharmacovigilance: Current Progress in Detecting Medication and Adverse Drug Events from Electronic Health Records. Drug Saf. 2019 01; 42(1):95-97.
-
Fantasia HC, Vooys KM. Public Health Implications of Counterfeit Medications. Nurs Womens Health. 2018 Jun; 22(3):264-268.
-
Bird ST, Gelperin K, Taylor L, Sahin L, Hammad H, Andrade SE, Mohamoud MA, Toh S, Hampp C. Enrollment and Retention in 34 United States Pregnancy Registries Contrasted with the Manufacturer's Capture of Spontaneous Reports for Exposed Pregnancies. Drug Saf. 2018 01; 41(1):87-94.
-
Iyer G, Marimuthu SP, Segal JB, Singh S. An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System. Drug Saf. 2017 09; 40(9):799-808.
-
Marimuthu SP, Iyer G, Segal JB, Singh S. Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: a pilot study. J Comp Eff Res. 2017 Jul; 6(5):437-447.